Acadia Pharma’s plan to develop pimavanserin as a treatment for additional indications is in disarray after the drug failed a phase 3 trial in schizophrenia.
Acadia Pharma's attempts to extend the indications of its Nuplazid drug in the US to include Alzheimer's disease-related psychosis have suffered another major setback.
Acadia Pharma's trofinetide has hit its efficacy targets in a phase 3 trial involving girls with the devastating neurological disorder Rett syndrome, although safety has dampened enthusiasm
The unexpected approval and lofty pricing of Biogen's Alzheimer's therapy Aduhelm is clearly the biopharma event of the year so far, but what are the broader implications for the industry a
